Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE® STn-KLH cancer vaccine
- 1 June 2000
- journal article
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 25 (12), 1233-1241
- https://doi.org/10.1038/sj.bmt.1702430
Abstract
The purpose of this study was to evaluate the toxicity and potential efficacy of administering the THERATOPE STn-KLH cancer vaccine to ovarian and breast cancer patients after an autologous stem cell transplant. Forty patients (11 high-risk stage II/III breast cancer, 22 stage IV breast cancer, and seven stage III/IV ovarian cancer patients) were treated with high-dose chemotherapy followed by autologous/syngeneic stem cell rescue and vaccination with THERATOPE STn-KLH (Sialyl-Tn-KLH with Detox-B Stable Emulsion). Each patient was scheduled to receive a total of five vaccinations beginning on days 30-151 after stem cell infusion. The vaccine was well tolerated. Induration and erythema at the site of injection were the most common side-effects. When one compares the outcome of patients vaccinated with 66 breast and ovarian cancer patients who were not, following risk-adjustment analysis, vaccinated patients appeared more likely to survive (P = 0.07) and less likely to relapse (P = 0. 10). Vaccinated patients with the greatest specific lytic activity against STn+OVCAR tumor cells relative to nonspecific killing of Daudi cells tended to remain in remission longer than patients who displayed less specific immune activity (P = 0.057). We conclude that the THERATOPE STn-KLH cancer vaccine is well tolerated in breast and ovarian cancer patients after autologous transplant and, while not statistically significant, the trends in data support the concept that THERATOPE vaccine may decrease the risk for relapse and death and thus warrants further study. Bone Marrow Transplantation (2000) 25, 1233-1241.Keywords
This publication has 31 references indexed in Scilit:
- High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancerBone Marrow Transplantation, 1998
- Enhancing the Effect of THERATOPE STn-KLH Cancer Vaccine in Patients with Metastatic Breast Cancer by Pretreatment with Low-Dose Intravenous CyclophosphamideJournal of Immunotherapy, 1996
- Antibodies Against Mucin-Associated Sialyl-Tn Epitopes Correlate with Survival of Metastatic Adenocarcinoma Patients Undergoing Active Specific Immunotherapy with Synthetic STn VaccineJournal of Immunotherapy, 1996
- CD69+ and HLA‐DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: Correlations with survival following active specific immunotherapyInternational Journal of Cancer, 1995
- Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvantCancer Immunology, Immunotherapy, 1993
- Immunohistochemical Evaluation of Sialosyl-Tn Antigens in Various Ovarian CarcinomasGynecologic Oncology, 1993
- Gene-marking to trace origin of relapse after autologous bone-marrow transplantationThe Lancet, 1993
- Immunogenicity of Haemophilus influenzae Type b Conjugate Vaccine in Allogeneic Bone Marrow RecipientsThe Journal of Infectious Diseases, 1992
- Antitumor Activity and Immune Responses Induced by a Recombinant Carcinoembryonic Antigen-Vaccinia Virus VaccineJNCI Journal of the National Cancer Institute, 1992
- RECOVERY OF IN VIVO CELLULAR IMMUNITY AFTER HUMAN MARROW GRAFTINGTransplantation, 1984